Skip to content
Sonic
AI
Sonic
AI
Home
Discover
Ask Sonic
Projects
Use with Claude or ChatGPT
Show me around
Request source or feature
Big Pharma Fails 50% of the Time in Phase Three. AI Can Fix That | Vin Singh, BullFrog AI, Sonic AI
Home
/
Eye On A.I.
/
Big Pharma Fails 50% of the Time in Phase Three. AI Can Fix That | Vin Singh, BullFrog AI
Eye On A.I.
Notify me
•
Jul 5, 2026
•
49:49
Interview
Big Pharma Fails 50% of the Time in Phase Three. AI Can Fix That | Vin Singh, BullFrog AI
Vin Singh
(Chairman, Founder, and CEO, Bullfrog AI, guest)
Get the full transcript next time Eye On A.I. releases an episode
Summary, key quotes, top claims, and the searchable transcript — emailed automatically. No card needed.
Sign up
Executive Summary
Bullfrog AI is leveraging a proprietary AI platform, licensed from Johns Hopkins APL, to de-risk the costly and failure-prone drug development process, which sees 50% failure rates in Phase 3 trials.
The company offers an end-to-end suite of solutions including BF Prep for data cleaning, BF Leap for causal AI analysis and discovery, and BF Arenas for prioritizing targets using LLMs.
Bullfrog AI's business model is to be a technology provider to large pharmaceutical companies, which are increasingly seeking to own proprietary AI models, positioning Bullfrog as a key partner and potential acquisition target.
Key proof points include identifying biological drivers for neuropsychiatric diseases from a unique dataset and identifying a patient subgroup in a pancreatic cancer trial with a threefold increase in survival.
Continue your research
Keep pulling the thread on Vin Singh.
De-risking Drug Development with AI
The AI Technology Stack for Pharma
8
quotes
Transcript
Key Arguments
Analysis
Quotes & Entities
8
Related
Loading transcript...
Processed Jul 5, 2026
Daily intelligence brief →
yt-dlp + mlx-whisper + Gemini